ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts

Biochemical Pharmacology

Volumn 79, Issue 3, 2010, Pages 339-349

  Ugarenko, Michal ^a   Nudelman, Abraham ^b   Rephaeli, Ada ^c   Kimura, Ken Ichi ^d   Phillips, Don R ^a   Cutts, Suzanne M ^a  

^a LA TROBE UNIVERSITY   (Australia)

^b BAR ILAN UNIVERSITY   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d IWATE UNIVERSITY   (Japan)

Author keywords

ABT 737; AN 9; Bcl 2; Doxorubicin; Drug DNA adducts

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; AN 158; AN 193; ANTINEOPLASTIC AGENT; DOXORUBICIN; MITOXANTRONE; PIVALOYLOXYMETHYL BUTYRATE; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA ADDUCT; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BIPHENYL COMPOUNDS; DNA ADDUCTS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HL-60 CELLS; HUMANS; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 70449635154     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.09.004     Document Type: Article

References (54)

1. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57 (1999) 727-741
2. Aisner J., Whitacre M.Y., Budman D.R., Propert K., Strauss G., Van Echo D.A., et al. Cisplatin, doxorubicin, cyclophosphamide, and etoposide combination chemotherapy for small-cell lung cancer. Cancer Chemother Pharmacol 29 (1992) 435-438
3. Park S.H., Lee Y., Han S.H., Kwon S.Y., Kwon O.S., Kim S.S., et al. Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer 6 (2006) 3
4. Cutts S.M., Swift L.P., Rephaeli A., Nudelman A., and Phillips D.R. Recent advances in understanding and exploiting the activation of anthracyclines by formaldehyde. Curr Med Chem Anticancer Agents 5 (2005) 431-447
5. Tewey K.M., Rowe T.C., Yang L., Halligan B.D., and Liu L.F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226 (1984) 466-468
6. Swift L.P., Rephaeli A., Nudelman A., Phillips D.R., and Cutts S.M. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 66 (2006) 4863-4871
7. Cullinane C., and Phillips D.R. Induction of stable transcriptional blockage sites by adriamycin: GpC specificity of apparent adriamycin-DNA adducts and dependence on iron(III) ions. Biochemistry 29 (1990) 5638-5646
8. Wang A.H., Gao Y.G., Liaw Y.C., and Li Y.K. Formaldehyde cross-links daunorubicin and DNA efficiently: HPLC and X-ray diffraction studies. Biochemistry 30 (1991) 3812-3815
9. Taatjes D.J., Gaudiano G., Resing K., and Koch T.H. Alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J Med Chem 39 (1996) 4135-4138
10. Zeman S.M., Phillips D.R., and Crothers D.M. Characterization of covalent adriamycin-DNA adducts. Proc Natl Acad Sci USA 95 (1998) 11561-11565
11. Cutts S.M., Parker B.S., Swift L.P., Kimura K.I., and Phillips D.R. Structural requirements for the formation of anthracycline-DNA adducts. Anticancer Drug Des 15 (2000) 373-386
12. Taatjes D.J., Gaudiano G., Resing K., and Koch T.H. Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J Med Chem 40 (1997) 1276-1286
13. Coldwell K.E., Cutts S.M., Ognibene T.J., Henderson P.T., and Phillips D.R. Detection of adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant adriamycin concentrations. Nucleic Acids Res 36 (2008) e100
14. Kato S., Burke P.J., Fenick D.J., Taatjes D.J., Bierbaum V.M., and Koch T.H. Mass spectrometric measurement of formaldehyde generated in breast cancer cells upon treatment with anthracycline antitumor drugs. Chem Res Toxicol 13 (2000) 509-516
15. Kato S., Burke P.J., Koch T.H., and Bierbaum V.M. Formaldehyde in human cancer cells: detection by preconcentration-chemical ionization mass spectrometry. Anal Chem 73 (2001) 2992-2997
16. Nudelman A., Ruse M., Aviram A., Rabizadeh E., Shaklai M., Zimrah Y., et al. Novel anticancer prodrugs of butyric acid. 2. J Med Chem 35 (1992) 687-694
17. Nudelman A., Gnizi E., Katz Y., Azulai R., Cohen-Ohana M., Zhuk R., et al. Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases. Eur J Med Chem 36 (2001) 63-74
18. Rephaeli A., Rabizadeh E., Aviram A., Shaklai M., Ruse M., and Nudelman A. Derivatives of butyric acid as potential anti-neoplastic agents. Int J Cancer 49 (1991) 66-72
19. Siu L.L., Von Hoff D.D., Rephaeli A., Izbicka E., Cerna C., Gomez L., et al. Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units. Invest New Drugs 16 (1998) 113-119
20. Kasukabe T., Rephaeli A., and Honma Y. An anti-cancer derivative of butyric acid (pivalyloxmethyl butyrate) and daunorubicin cooperatively prolong survival of mice inoculated with monocytic leukaemia cells. Br J Cancer 75 (1997) 850-854
21. Reid T., Valone F., Lipera W., Irwin D., Paroly W., Natale R., et al. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex AN-9) in advanced non-small cell lung cancer. Lung Cancer 45 (2004) 381-386
22. Cutts S.M., Rephaeli A., Nudelman A., Hmelnitsky I., and Phillips D.R. Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res 61 (2001) 8194-8202
23. Cutts S.M., Swift L.P., Pillay V., Forrest R.A., Nudelman A., Rephaeli A., et al. Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate. Mol Cancer Ther 6 (2007) 1450-1459
24. Del Poeta G., Venditti A., Del Principe M.I., Maurillo L., Buccisano F., Tamburini A., et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 101 (2003) 2125-2131
25. Kirkin V., Joos S., and Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 1644 (2004) 229-249
26. Uren R.T., Dewson G., Chen L., Coyne S.C., Huang D.C., Adams J.M., et al. Mitochondrial permeabilization relies on BH3 ligands engaging multiple prosurvival Bcl-2 relatives, not Bak. J Cell Biol 177 (2007) 277-287
27. Willis S.N., Fletcher J.I., Kaufmann T., van Delft M.F., Chen L., Czabotar P.E., et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315 (2007) 856-859
28. Zong W.X., Lindsten T., Ross A.J., MacGregor G.R., and Thompson C.B. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 15 (2001) 1481-1486
29. Hinds M.G., and Day C.L. Regulation of apoptosis: uncovering the binding determinants. Curr Opin Struct Biol 15 (2005) 690-699
30. Letai A., Sorcinelli M.D., Beard C., and Korsmeyer S.J. Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell 6 (2004) 241-249
31. Lu C., and Shervington A. Chemoresistance in gliomas. Mol Cell Biochem 312 (2008) 71-80
32. Zhang L., Ming L., and Yu J. BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist Update 10 (2007) 207-217
33. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (2005) 677-681
34. Del Gaizo Moore V., Brown J.R., Certo M., Love T.M., Novina C.D., and Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 117 (2007) 112-121
35. Del Gaizo Moore V., Schlis K.D., Sallan S.E., Armstrong S.A., and Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 111 (2008) 2300-2309
36. Konopleva M., Contractor R., Tsao T., Samudio I., Ruvolo P.P., Kitada S., et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10 (2006) 375-388
37. Tahir S.K., Yang X., Anderson M.G., Morgan-Lappe S.E., Sarthy A.V., Chen J., et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 67 (2007) 1176-1183
38. Kuroda J., Puthalakath H., Cragg M.S., Kelly P.N., Bouillet P., Huang D.C., et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 103 (2006) 14907-14912
39. Kimura K., Nakayama S., Koyama T., Shimada S., Nawaguchi N., Miyata N., et al. SN-07 chromophore: an anthracycline antibiotic from the macromolecular antibiotic SN-07. J Antibiot 40 (1987) 1353-1355
40. Buzdar A.U., Marcus C., Smith T.L., and Blumenschein G.R. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 55 (1985) 2761-2765
41. Post G.C., Barthel B.L., Burkhart D.J., Hagadorn J.R., and Koch T.H. Doxazolidine, a proposed active metabolite of doxorubicin that cross-links DNA. J Med Chem 48 (2005) 7648-7657
42. Burkhart D.J., Barthel B.L., Post G.C., Kalet B.T., Nafie J.W., Shoemaker R.K., et al. Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterases. J Med Chem 49 (2006) 7002-7012
43. Barthel B.L., Torres R.C., Hyatt J.L., Edwards C.C., Hatfield M.J., Potter P.M., et al. Identification of human intestinal carboxylesterase as the primary enzyme for activation of a doxazolidine carbamate prodrug. J Med Chem 51 (2008) 298-304
44. van Delft M.F., Wei A.H., Mason K.D., Vandenberg C.J., Chen L., Czabotar P.E., et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10 (2006) 389-399
45. Chen S., Dai Y., Harada H., Dent P., and Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 67 (2007) 782-791
46. Lin X., Morgan-Lappe S., Huang X., Li L., Zakula D.M., Vernetti L.A., et al. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 26 (2007) 3972-3979
47. Willis S.N., and Adams J.M. Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 17 (2005) 617-625
48. Zeng X., Chen L., Jost C.A., Maya R., Keller D., Wang X., et al. MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 19 (1999) 3257-3266
49. Spencer D.M., Bilardi R.A., Koch T.H., Post G.C., Nafie J.W., Kimura K., et al. DNA repair in response to anthracycline-DNA adducts: a role for both homologous recombination and nucleotide excision repair. Mutat Res 638 (2008) 110-121
50. Zhou P., Levy N.B., Xie H., Qian L., Lee C.Y., Gascoyne R.D., et al. MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. Blood 97 (2001) 3902-3909
51. Aichberger K.J., Mayerhofer M., Krauth M.T., Skvara H., Florian S., Sonneck K., et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 105 (2005) 3303-3311
52. Sano M., Nakanishi Y., Yagasaki H., Honma T., Oinuma T., Obana Y., et al. Overexpression of anti-apoptotic Mcl-1 in testicular germ cell tumours. Histopathology 46 (2005) 532-539
53. Certo M., Del Gaizo Moore V., Nishino M., Wei G., Korsmeyer S., Armstrong S.A., et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9 (2006) 351-365
54. Tse C., Shoemaker A.R., Adickes J., Anderson M.G., Chen J., Jin S., et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68 (2008) 3421-3428